BridgeBio Oncology Therapeutics (BBOT) vs Oramed Pharmaceuticals (ORMP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Oramed Pharmaceuticals (ORMP) has outperformed BridgeBio Oncology Therapeutics (BBOT) over the past year, gaining 38.4% versus a loss of 85.4%. Oramed Pharmaceuticals is the larger company by market cap ($155.2 million vs $145.3 million), about 1.1 times the size. On valuation, Oramed Pharmaceuticals trades at a lower trailing P/E (1.0x vs 3.4x for BridgeBio Oncology Therapeutics).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BBOT | ORMP |
|---|---|---|
| Share price | $1.81 | $3.57 |
| Market cap | $145.25M | $155.24M |
| 1-day change | -2.69% | -3.25% |
| YTD return | -85.54% | +25.26% |
| 1-year return | -85.39% | +38.37% |
| 5-year return | — | -82.34% |
| P/E ratio (TTM) | 3.42 | 1.05 |
| EPS (TTM) | $0.53 | $3.41 |
| Dividend yield | 0.00% | 7.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $2.00M |
| Net income (latest FY) | $-134.04M | $64.05M |
| Gross margin | — | 0.65% |
| Operating margin | — | -754.40% |
| Net margin | — | 3202.50% |
| 52-week high | $14.87 | $5.47 |
| 52-week low | $1.79 | $2.52 |
| Distance from 52-week high | -87.83% | -34.73% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +1060.22% | +96.08% |
| Average volume | 631.56K | 173.38K |
| Shares outstanding | 80.25M | 43.49M |
| Employees | 92 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ORMP has outperformed BBOT by 123.8 percentage points over the past year.
- BridgeBio Oncology Therapeutics trades at a higher earnings multiple (3.4x vs 1.0x trailing P/E).
- Oramed Pharmaceuticals offers a meaningfully higher dividend yield (7.00% vs 0.00%).
About BridgeBio Oncology Therapeutics
BBOT stock →BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models.
Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees
About Oramed Pharmaceuticals
ORMP stock →Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins.
Health Care · Biotechnology: Pharmaceutical Preparations
BBOT vs ORMP FAQ
Which is bigger, BridgeBio Oncology Therapeutics or Oramed Pharmaceuticals?
Oramed Pharmaceuticals (ORMP) is larger, with a market capitalization of $155.24M compared with $145.25M for BridgeBio Oncology Therapeutics (BBOT).
Which stock has performed better over the past year, BBOT or ORMP?
ORMP returned +38.37% over the past 12 months, compared with -85.39% for BBOT (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, BBOT or ORMP?
ORMP has the lower trailing P/E at 1.0, versus 3.4 for BBOT. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, BridgeBio Oncology Therapeutics or Oramed Pharmaceuticals?
Oramed Pharmaceuticals pays a dividend yielding 7.00%, while BridgeBio Oncology Therapeutics does not currently pay a regular dividend.
Are BridgeBio Oncology Therapeutics and Oramed Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.